Goldman Sachs
INBX icon

Goldman Sachs’s Inhibrx INBX Stock Holding History

Goldman Sachs’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32M Buy
338,176
+243,102
+256% +$24.4M ﹤0.01% 2196
2026
Q1 		$6.39M Sell
95,074
-5,543
-6% -$411K ﹤0.01% 3467
2025
Q4 		$7.95M Buy
100,617
+74,651
+287% +$5.09M ﹤0.01% 3315
2025
Q3 		$875K Buy
25,966
+14,877
+134% +$366K ﹤0.01% 5119
2025
Q2 		$158K Sell
11,089
-6,076
-35% -$78.5K ﹤0.01% 5721
2025
Q1 		$240K Sell
17,165
-40,282
-70% -$547K ﹤0.01% 5559
2024
Q4 		$885K Buy
57,447
+35,685
+164% +$544K ﹤0.01% 4902
2024
Q3 		$341K Buy
+21,762
New +$306K ﹤0.01% 5243

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs's INBX Position: Q2 2026 in Review

Goldman Sachs increased its Inhibrx (INBX) stake by 256% in Q2 2026, buying an estimated $24.4M and bringing the position to 338,176 shares worth $32M. The position accounts for ﹤0.01% of the portfolio, ranked #2196.

Goldman Sachs first reported a position in INBX in Q3 2024 and has held it in 8 quarters since. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Goldman Sachs held 338,176 shares of Inhibrx worth $32M as of Q2 2026.
  • Goldman Sachs bought 243,102 Inhibrx shares in Q2 2026, an estimated $24.4M.
  • Inhibrx made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2196 holding.
  • Goldman Sachs first reported a position in Inhibrx in Q3 2024 and has held it in 8 quarters since.
  • 162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.